Mucosal and circulating immunity against SARS-CoV-2 among healthcare professionals working with COVID-19 patients

Mucosal and circulating immunity against SARS-CoV-2 among healthcare professionals working with COVID-19 patients - Immunity screening COVID-19

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON49305

Enrollment

350

Registered

2020-07-27

Start date

2020-08-11

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 SARS-CoV-2

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: healthcare professionals working or having worked (in a department) with COVID-19 patients within the LUMC

Exclusion criteria

Exclusion criteria: below 18 years old

Design outcomes

Primary

Measure	Time frame
The main study outcome will be the prevalence of mucosal IgA and circulating IgA and IgG SARS-CoV-2 antibodies.	—

Secondary

Measure	Time frame
Secondary study outcomes will be the evolution of the titers of these mucosal IgA and circulating IgA and IgG SARS-CoV-2 antibodies over time and the relation of their presence to symptom severity. Furthermore, the potential relation between the presence of mucosal IgA SARS-CoV-2 antibodies and the presence of PCR-detectable coronaviruses other than SARS-CoV-2 in saliva will be assessed.	—

Countries

Netherlands

Outcome results